ANI Pharmaceuticals (NASDAQ:ANIP) Given New $114.00 Price Target at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP) had its target price increased by Guggenheim from $86.00 to $114.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a report on Monday, August 11th. Finally, Piper Sandler restated an “overweight” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $88.25.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $95.20 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $96.56. The firm’s 50 day moving average price is $76.86 and its two-hundred day moving average price is $68.62. The firm has a market cap of $2.07 billion, a P/E ratio of -123.63 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. During the same period last year, the company earned $1.02 earnings per share. The firm’s revenue was up 53.2% compared to the same quarter last year. On average, analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,763 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $91.10, for a total value of $160,609.30. Following the completion of the sale, the senior vice president owned 62,896 shares of the company’s stock, valued at approximately $5,729,825.60. The trade was a 2.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Antonio R. Pera sold 7,292 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $94.94, for a total transaction of $692,302.48. Following the sale, the director directly owned 22,660 shares of the company’s stock, valued at $2,151,340.40. This represents a 24.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 412,830 shares of company stock valued at $36,382,434 in the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ANIP. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after purchasing an additional 473,097 shares during the period. Rubric Capital Management LP raised its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after acquiring an additional 200,998 shares in the last quarter. Aberdeen Group plc raised its stake in ANI Pharmaceuticals by 76.1% during the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after acquiring an additional 181,134 shares in the last quarter. Woodline Partners LP acquired a new position in ANI Pharmaceuticals during the first quarter worth about $11,144,000. Finally, Teacher Retirement System of Texas raised its stake in ANI Pharmaceuticals by 3,156.3% during the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock worth $9,617,000 after acquiring an additional 142,854 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.